- Request for follow-up
- Medical Information
- Other Information
Congress Publications
For Information on past and upcoming Medical Congresses in which argenx is presenting clincial research and data, please select the disease area of interest
Myasthenia Gravis
European Academy of Neurology (EAN)
July 1-4, 2023
-
Budapest, Hungary
European Academy of Neurology (EAN)
July 1-4, 2023
-
Budapest, Hungary
Posters
- Efgartigimod Demonstrates Consistent Improvements in Patients With gMG Regardless of Prior Treatment Failures
- Long-Term Safety, Tolerability, And Efficacy of Efgartigimod In Patients With gMG: Final Analyses From The ADAPT+ Study
- Efgartigimod Demonstrates Consistent Magnitude of Response Across Subgroups of Patients With gMG
- Overview of the Safety Profile of Efgartigimod From Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
- Higher Need For Medical Resources Among Moderate-To-Severe Myasthenia Gravis Patients In Comparison To The General Population: Analysis Of Two Digital Observational Datasets
- The burden MG patients experience in fatigue, sleep, and mental health compared to the general population
- The Burden MG Patients Experience In Terms Of Utilities And Health Care Utilization: Comparison With The General Population
- A Study Examining The Concordance Between Patient And Physician Assessment Of The MG-ADL
- Evidence-based expert consensus guidance for ongoing assessment of generalised myasthenia gravis (gMG)
- Gender-specific analysis of efficacy of efgartigimod in patients with generalised myasthenia gravis: Subanalysis of the randomized Phase 3 ADAPT trial
- A real world experience with Efgartigimod in generalized Myasthenia gravis in a national reference centre
Oral Presentations
Japanese Society of Neurology (JSN)
May 31 - June 3, 2023
-
Tokyo, Japan
Japanese Society of Neurology (JSN)
May 31 - June 3, 2023
-
Tokyo, Japan
Posters
American Academy of Neurology (AAN)
April 22-27, 2023
-
Boston, MA
American Academy of Neurology (AAN)
April 22-27, 2023
-
Boston, MA
Posters
- Long-Term Safety, Tolerability, and Efficacy of Subcutaneous EfgartigimodPH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
- Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients With Generalized Myasthenia Gravis
- Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration
- Overview of the Safety Profile from Efgartigimod Clinical Trials in Participants with Diverse IgG-Mediated Autoimmune Diseases
- Long-term Safety, Tolerability, and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Concluding Analyses From the ADAPT+ Study
- Patient Support Program Needs In Patients Diagnosed With Generalized Myasthenia Gravis Facing Social Determinants of Health Challenges
Muscular Dystrophy Association (MDA)
March 19-22, 2023
-
Dallas, TX
Muscular Dystrophy Association (MDA)
March 19-22, 2023
-
Dallas, TX
Posters
- Pharmacodynamic Noninferiority Study Comparing Subcutaneous Efgartigimod PH20 With Intravenous Efgartigimod: Results of Phase 3 ADAPTsc Study
- Efficacy, Safety, and Tolerability of Efgartigimod in AChR-Ab- Patients With Generalized Patients With Generalized Myasthenia Gravis: Interim Analysis of ADAPT/ADAPT+ Studies
- Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Across Patient Subgroups, Including Early in Diagnosis
Oral Presentations
- PRESENTATION: Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial dostarlimab
- PRESENTATION: Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ES0-1 TCR T cells (Letetresgene autolueucel)
Carrell Krusen
February 23-24, 2023
-
Dallas, TX
Carrell Krusen
February 23-24, 2023
-
Dallas, TX
Oral Presentations
- PRESENTATION: Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial dostarlimab
- PRESENTATION: Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ES0-1 TCR T cells (Letetresgene autolueucel)
American Neurological Association (ANA)
October 22-25, 2022
-
Chicago, Illinois
American Neurological Association (ANA)
October 22-25, 2022
-
Chicago, Illinois
Myology
September 12-15, 2022
-
Nice, France
Myology
September 12-15, 2022
-
Nice, France
Posters
- Long-term safety and efficacy of efgartigimod in patients with generalised myasthenia gravis
- CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT
- Efgartigimod improved qualify of life gMG: a randomised, double-blinded, placebo-controlled, phase 3 trial (ADAPT)
- Baseline Characteristics of Patients with Myasthenia Gravis Enrolled in an Expanded Access Programme for Efgartigimod
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
September 21-24, 2022
-
Nashville, TN
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
September 21-24, 2022
-
Nashville, TN
Posters
- THE EFFECT OF OBESITY IN EFFICACY AND SAFETY IN THE ADAPT TRIAL OF EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS
- CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT
- Study Design of Intravenous Efgartigimod in Juvenile Generalized Myasthenia Gravis
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT+ STUDY
- RESPONSE TO CORONAVIRUS 2019 VACCINATION IN PATIENTS RECEIVING EFGARTIGIMOD
- EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD IN ANTI-ACETYLCHOLINE RECEPTOR AUTOANTIBODY SERONEGATIVE PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTEGRATED INTERIM ANALYSIS OF ADAPT AND ADAPT+ STUDIES
- EFFECTS OF EFGARTIGIMOD TREATMENT ON HUMORAL AND CELLULAR IMMUNE RESPONSES: ANALYSIS OF T-CELL-DEPENDENT ANTIBODY RESPONSE IN CYNOMOLGUS MONKEYS
- SAFETY AND TOLERABILITY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTEGRATED INTERIM ANALYSIS OF INFECTION RISK AND HEMATOLOGICAL CHANGES
- PRESENTATION: Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial dostarlimab
- PRESENTATION: Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ES0-1 TCR T cells (Letetresgene autolueucel)
Myasthenia Gravis Foundation of America (MGFA)
September 21-24, 2022
-
Nashville, TN
Myasthenia Gravis Foundation of America (MGFA)
September 21-24, 2022
-
Nashville, TN
Posters
- Trends in Hospital Admissions and Readmissions for Patients with MG from U.S. National Research Databases
- Risk benefit analysis of treatments for general myasthenia gravis
- REAL-WORLD TREATMENT PATTERNS IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS INITIATING INTRAVENOUS IMMUNOGLOBULIN IN THE UNITED STATES
- A PHASE 3B OPEN-LABEL STUDY TO FURTHER INDIVIDUALIZE EFGARTIGIMOD TREATMENT OPTIONS FOR PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
- Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Across Patient Subgroups, Including Early in Diagnosis
- A PHARMACODYNAMIC NONINFERIORITY STUDY COMPARING SUBCUTANEOUS INJECTIONS OF EFGARTIGIMOD PH20 WITH INTRAVENOUS INFUSIONS OF EFGARTIGIMOD: RESULTS OF THE PHASE 3 ADAPT-SC STUDY
- Efficacy of Efgartigimod Treatment in Patients With Anti-Acetylcholine Receptor Antibody Negative Myasthenia Gravis: Clinical Trial and Real-World Data
- PRESENTATION: Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial dostarlimab
- PRESENTATION: Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ES0-1 TCR T cells (Letetresgene autolueucel)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Peripheral Nerve Society (PNS)
June 17-20, 2023
-
Copenhagen, Denmark
Peripheral Nerve Society (PNS)
June 17-20, 2023
-
Copenhagen, Denmark
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
September 21-24, 2022
-
Nashville, TN
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
September 21-24, 2022
-
Nashville, TN
- PRESENTATION: Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial dostarlimab
- PRESENTATION: Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ES0-1 TCR T cells (Letetresgene autolueucel)
